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Genome-wide association studies (GWAS) and candidate gene analyses have led to the discovery of several
dozen genetic polymorphisms associated with breast cancer susceptibility, many of which are considered well-
established risk factors for the disease. Despite attempts to replicate these same variant-disease associations in
African Americans, the evaluable populations are often too small to produce precise or consistent results. We es-
timated the associations between 83 previously identified single nucleotide polymorphisms (SNPs) and breast can-
cer among Carolina Breast Cancer Study (1993–2001) participants using maximum likelihood, Bayesian, and
hierarchical methods. The selected SNPs were previous GWAS hits (n = 22), near-hits (n = 19), otherwise well-
established risk loci (n = 5), or located in the same genes as selected variants (n = 37). We successfully replicated
18 GWAS-identified SNPs in whites (n = 2,352) and 10 in African Americans (n = 1,447). SNPs in the fibroblast
growth factor receptor 2 gene (FGFR2) and the TOC high mobility group box family member 3 gene (TOX3)
were strongly associated with breast cancer in both races. SNPs in the mitochondrial ribosomal protein S30
gene (MRPS30),mitogen-activated protein kinase kinase kinase 1gene (MAP3K1), zinc finger,MIZ-type containing
1 gene (ZMIZ1), andH19, imprintedmaternally expressed transcript gene (H19) were associatedwith breast cancer
in whites, and SNPs in the estrogen receptor 1 gene (ESR1) and H19 gene were associated with breast cancer in
African Americans. We provide precise and well-informed race-stratified odds ratios for key breast cancer–related
SNPs. Our results demonstrate the utility of Bayesianmethods in genetic epidemiology and provide support for their
application in small, etiologically driven investigations.
Bayesian analysis; breast cancer; genetics; genome-wide association studies; GWAS replication; race; single
nucleotide polymorphisms
Abbreviations: GWAS, genome-wide association study(ies); LD, linkage disequilibrium;MLE,maximum likelihood estimation; SNP,
single nucleotide polymorphism.
As of June 2013, a total of 74 single nucleotide polymor-
phisms (SNPs) met the criterion for inclusion in the National
Human Genome Research Institute’s database of genome-
wide association study (GWAS) hits, which requires a P
value of less than 10−5 in at least 1 of 25 breast cancer
GWAS (1). Most of these SNPs were consistently associated
with the disease in subsequent investigations among women
of European or Asian descent (Web Appendix 1, available at
http://aje.oxfordjournals.org/), but attempts to replicate these
findings in African-American women have been largely un-
successful (2–12). In general, the search for African-American-
–specific risk variants has made slow progress, with few in-
sights to explain the tendency for African-American women
to have more aggressive, less treatable disease subtypes (13–
16) and markedly higher breast cancer–specific mortality
than whites (32.7 vs. 23.7 deaths per 100,000 US women
per year in 2000–2009) (17).
Allele frequencies and linkage disequilibrium (LD) struc-
tures vary by race, with African Americans exhibiting gener-
ally weaker between-SNP correlations and smaller LD blocks
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(18, 19). Because each SNP represents all correlated variants,
SNPs associated with breast cancer in African Americans
correspond to a narrower genomic region than SNPs associ-
ated with the disease in whites. Therefore, studying African
Americans should help us identify causal loci and improve
our understanding of disease etiology. Unfortunately, most
of the studies of genetic breast cancer risk factors carried
out in African Americans have been small and therefore
have lacked the necessary statistical power to reliably differ-
entiate between null associations and odds ratios of 1.1–1.3, a
typical range for GWAS-identified risk variants in other
populations (1, 20).
Given existing knowledge about effect size, as well as in-
formation about the genome’s correlation structure, Bayesian
statistical methods may be useful tools for enhancing the
analysis of race-specific genetic risk factors for breast cancer.
Avariety of Bayesian-based methods have been proposed for
use in genetic epidemiology (21–27), but in the current study,
we focused on 2 of the most basic applications, hierarchical
modeling and Bayesian regression. Our goal was to obtain
valid and precise effect estimates by capitalizing on existing
information.
To further our understanding of genetic risk factors for the
disease, we examined the association between breast cancer
and several candidate SNPs by using traditional maximum
likelihood methods and both Bayesian approaches. All of
the selected SNPs were located on genes with strong prior ev-
idence of an association with breast cancer from GWAS and
candidate gene investigations. We assessed the relationship
between these SNPs and breast cancer risk using data from
the Carolina Breast Cancer Study, a population-based case-
control study of white and African-American women.
MATERIALS AND METHODS
Study population
Cases were identified using the North Carolina Central
Cancer Registry’s rapid case ascertainment program (28).
Women were eligible for the study if they were diagnosed
with invasive breast cancer in 1993–2001, were 20–74 years
of age at diagnosis, and lived in 1 of 24 North Carolina coun-
ties. Womenwith in situ disease were eligible if they had duc-
tal carcinoma in situ with microinvasion of 2 mm or more or
lobular carcinoma in situ. To ensure approximately equal rep-
resentation of African Americans and non–African Ameri-
cans, as well as both pre- and postmenopausal women, we
randomly sampled breast cancer cases at disproportionate
rates based on race and age.
Controls aged 20–64 or 65–74 years were selected from re-
cords of the North Carolina Department of Motor Vehicles
(Raleigh, North Carolina) and the Health Care Financing Ad-
ministration (Centers for Medicare & Medicaid Services,
Baltimore, Maryland), respectively. Controls were probability-
-matched to cases on race and 5-year age group (29). Women
with a history of breast cancer were ineligible. All partici-
pants provided informed consent, and study procedures were
approved by the institutional review board of the University
of North Carolina.
A study nurse administered a questionnaire to each partic-
ipant during an in-home visit. The survey included questions
on basic demographic factors, known or suspected breast
cancer risk factors, and medical and family history. Addition-
ally, the nurse drew 30 mL of blood. The overall response rate
was 77% for cases and 57% for controls. Of those enrolled,
88% of cases and 90% of controls provided sufficient blood
samples for inclusion in genotype analyses, leaving a total
sample size of 2,013 cases (1,247 white and 766 African
American) and 1,786 controls (1,105 white and 681 African
American). We excluded 166 persons who identified them-
selves as having a race/ethnicity other than African American
or non-Hispanic white.
SNP selection
Initially, we selected candidate SNPs with P values less
than 10−5 in any of 8 early breast cancer GWAS (30–37) or
2 GWAS follow-up studies (38, 39). We also evaluated sev-
eral SNPs from these initial studies that had P values less than
10−5 in discovery-phase analyses. Lastly, we retained any
SNPs already genotyped in the study population that Zhang
et al. (40) determined had “cumulative evidence of an asso-
ciation” with breast cancer or that were located in the same
gene as a previously selected variant. In total, we selected
41 GWAS-identified SNPs, including 22 GWAS hits and
19 other strongly associated SNPs, as well as 5 SNPs from
the meta-analysis by Zhang et al. (40) and 37 SNPs from in-
cluded genes.We later excluded 6 SNPs with minor allele fre-
quencies less than 1% in white participants and 10 SNPs with
minor allele frequencies less than 1% in African Americans,
leaving a total of 77 and 73 SNPs, respectively.
All study participants were genotyped for 144 ancestry in-
formative markers, which were used to estimate each partic-
ipant’s proportion of African ancestry. Inclusion of this
variable in regression models should reduce confounding
due to population stratification (41, 42).
Genotype analysis
The SNPs included in this analysis were genotyped using
either a custom GoldenGate Genotyping Assay (Illumina,
Inc., San Diego, California) or a customized TaqMan panel
(Applied Biosystems, Inc., Foster City, California). Both pro-
cesses have been described previously (43, 44). All of the
SNPs included in this analysis passed quality control evalua-
tions, including examination of individual call rates and inspec-
tion of assay intensity data and genotype clustering images.
Statistical methods
We calculated risk allele frequencies and age and African
ancestry distributions for whites and African Americans sep-
arately. We tested for departures from Hardy-Weinberg equi-
librium in white and African-American controls using
Pearson’s χ2 test, and we reinspected the genotype clustering
images of SNPs with P values less than 0.05 in either popu-
lation for signs of poor genotype differentiation. SNPs were
retained if their genotypes formed discrete clusters with min-
imal overlap.
Breast Cancer Genetics, Race, and Bayesian Methods 383
Am J Epidemiol. 2014;179(3):382–394
The relationship between each risk variant and incident
breast cancer was assessed by using logistic regression. We
estimated odds ratios and 95% confidence intervals assuming
additive genetic models. The risk allele for each SNP was se-
lected a priori based on the meta-analysis by Zhang et al. (40)
or previous GWAS (30–39). We assumed that the risk allele
was the same for African Americans and whites unless the
majority of the statistically significant associations reported
indicated otherwise (2–5, 11, 12).
All models were stratified by race and adjusted for propor-
tion of African ancestry and age at diagnosis or selection. We
centered age at 50 years and ancestry at race-specific means.
An offset term was included to account for unequal sampling
by race and age group. We will herein refer to these frequent-
ist estimates as the maximum-likelihood estimation (MLE)
odds ratios.
Bayesian analysis
Bayes’ theorem states that the posterior probability distri-
bution for the parameter of interest given the observed data,
f(β|D), is proportional to the likelihood of the observed data,
L(β|D), multiplied by the prior probability distribution f(β)
(45, 46). Here, the likelihood function is the same as the
MLE likelihood, with the log odds of being a case given ex-





¼ β0 þ βjXj þWγ:
In this application, βj is the estimated log odds ratio of being a
breast cancer case for each copy of the risk allele at SNP j, and
γ is a vector of estimated log odds ratios for age and ancestry.
To incorporate the priors, we added a second stage to the
model, βj ¼ zjπþ δj, where zj is a j × 1 vector of 1 second, π
is the prior log odds ratio, and δj is assumed to be normally dis-
tributed with mean 0 and variance τ2. For each covariate, the
prior mean (π), variance (τ2), or both can either be estimated
directly from the data or assigned by the investigator. We use
the terms “full-Bayes” to indicate that all priors were assigned
independently of the data at hand, “empirical Bayes” when all
priors were estimated from the data, and “semi-Bayes” when
some priors were assigned and others were estimated (47).
We conducted both a full-Bayes analysis and a semi-Bayes
analysis, but did not use empirical Bayes methods, because
the near-0 τ2 generated from this rich data set caused over-
shrinkage of SNP-specific effect estimates. For full-Bayes
analyses, we assigned priors for the mean and τ2 of all covar-
iates. For the semi-Bayes analysis, we assigned a fixed τ2 to
the SNP parameters, but used LD block (i.e., haplotype)–
level odds ratio estimates to inform the SNPs’ prior mean π
and did not specify priors for any other covariates.
To obtain Bayesian (i.e., full-Bayes) log odds ratios, we as-
signed a null-centered, lognormal prior with a mean of 0 and
variance τ2∼ Γ−1 (3, 0.2) to each SNP, such that 95% of the
prior mass for each SNP–breast cancer odds ratio lay between
0.64 and 1.55 when τ2 was equal to its mode (0.05). As dis-
cussed previously, this range likely includes the true value for
any single SNP–breast cancer association. Each Bayesian
model included exactly 1 SNP ( j = 1).
We also assigned null-centered, lognormal priors for age
and ancestry, giving both parameters prior variances of 0.68.
These priors reflect our belief, with moderate uncertainty,
that these mean-centered covariates are weakly associated
with breast cancer. We placed a β0 ∼ N(0, 1,000) prior on
the intercept. In the absence of other information, this vague
prior shouldgenerate posterior intercept estimates nearly iden-
tical to the MLE estimates. We assumed that all priors were
independent.
For the semi-Bayes analysis, we used hierarchical model-
ing to integrate haplotype information (22, 48–50).More spe-
cifically, we used the estimated joint effect of all of the SNPs
in an LD block to inform the prior mean (π). If there was only
1 genotyped SNP in an LD block, π and βjwere identical, and
the hierarchical estimate was very similar to the MLE esti-
mate.We assigned fixed prior variances of 0.05 for each SNP.
The above grouping approach is valid as long as an ex-
changeability assumption is met. This assumption states that,
before evaluating the relationship between the exposures and
the outcome, there was no reason to suspect that any 1 exposure
in a group had a true log odds ratio different from the others in
that group. Because none of the included SNPs are known
causal variants, and all effects are evaluated in terms of risk al-
leles, we believe this assumption is acceptable in our setting.
For Bayesian methods, we present posterior geometric
mean odds ratios (i.e., antilogs of posterior mean log odds ra-
tios) and 95% posterior intervals. For the Bayesian analyses,
we ran 30,000 samples for each SNP model, discarding the
first 1,000 draws as a burn-in and retaining every fifth draw.
We inspected autocorrelation, trace, and density plots to ver-
ify that all posterior estimates converged appropriately.
LD blocks were determined by usingmethods proposed by
Gabriel et al. (51) and conducted in Haploview, version 4.2,
software (Broad Institute, Cambridge, Massachusetts) (52).
Bayesian models were analyzed using PROC MCMC or
PROC GLIMMIX in SAS, version 9.3, software (SAS Insti-
tute, Inc., Cary, North Carolina). Example code is provided
as Web Appendix 2.
GWAS-identified SNPs were considered successfully rep-
licated if their entire 95% posterior intervals fell above the
null, as were SNPs identified in the candidate gene meta-
analysis. More formal homogeneity tests comparing our find-
ings with the meta-analysis or initial GWAS estimates were
inappropriate, because these studies did not consistently re-
port odds ratios from additive genetic models.
RESULTS
As expected, age distributions were similar for cases and
controls, regardless of race. White cases and controls were 52
and 53 years of age at selection, on average, and African-
American cases and controls were 52 years of age, on average
(Web Table 1). Whites had approximately 7% African ances-
try and African Americans had 77%. More detailed descrip-
tions of the study population have been published elsewhere
(53) (Web Appendix 3).
Table 1 shows race-stratified risk allele frequencies and
Hardy-Weinberg equilibrium P values. Seven SNPs were not
inHardy-Weinbergequilibriumbyourcriterion (P<0.05).We
retained 6 of these, because their clustering images indicated
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good differentiation, and none failed Hardy-Weinberg equi-
librium tests in both races. We excluded the seventh SNP,
rs614367 (myeloma overexpressed gene (MYEOV)), after ob-
serving disparate clusters for the homozygous rare genotype
and finding evidence of allelic dropout.
MLE odds ratios for whites and African Americans are dis-
played in Tables 2 and 3, respectively. Confidence limit ratios
and posterior limit ratios for each model are displayed to fa-
cilitate comparisons of model precision.
Among whites in our study, 18 of the GWAS-identified
SNPs successfully replicated. All of the fibroblast growth fac-
tor receptor 2 gene (FGFR2) SNPs had relatively strong, posi-
tive associations with breast cancer (odds ratios (ORs) > 1.15),
as did both of the mitochondrial ribosomal protein S30 gene
(MRPS30) SNPs, 2 of the TOX high mobility group box fam-
ilymember 3 gene (TOX3) SNPs (rs3803662 and rs4784227),
rs889312 in mitogen-activated protein kinase kinase kinase 1
gene (MAP3K1), rs704010 in zinc finger, MIZ-type contain-
ing 1 gene (ZMIZ1), and rs2107425 in H19, imprinted mater-
nally expressed transcript gene (H19). The 95% confidence
interval for rs909116 in lymphocyte-specific protein 1 gene
(LSP1) excluded the null, but the Bayesian odds ratio was at-
tenuated and did not meet our replication criteria. Three other
FGFR2 SNPs (rs3750817, rs11200014, and rs2162540)
were strongly associated with breast cancer (OR > 1.2) in
whites.
None of the SNPs selected from the candidate gene meta-
analysis replicated, though several SNPs in ataxia telangiec-
tasia mutated gene (ATM) and tumor protein p53 gene (TP53)
were strongly associated with disease (|ln OR| > 0.15). The
original GWAS and meta-analysis odds ratios are provided
in Table 2 for further reference.
The most extreme example of the difference betweenMLE
and Bayesian estimates in whites in our study was for
rs3104746 in TOX3, a rare SNP (risk allele frequency = 2%)
with the highest MLE odds ratio (OR = 1.66). Here, the
Bayesian estimate was closer to the null (OR = 1.42) and
was more precise (MLE confidence limit ratio = 2.29 vs.
Bayesian posterior limit ratio = 2.01; Web Appendix 4,
Web Figure 1).
Ten of the GWAS-identified SNPs successfully replicated
in African Americans (Table 3 and Web Figure 2). This in-
cluded 9 SNPs in FGFR2 (ORs > 1.15) and rs2046210 in es-
trogen receptor 1 gene (ESR1). Two other GWAS-identified
SNPs, rs2107425 (in H19) and rs12443621 (in TOX3), had
95% posterior intervals that excluded the null, but both
were inversely associated with breast cancer and, thus, incon-
sistent with original reports. Two additional TOX3 SNPs
(rs3104746 and rs3112562) had odds ratios greater than
1.25 via either analysis method. Some of the ATM and
ESR1 MLE odds ratios were relatively strong, but none of
the SNPs from the candidate gene meta-analysis successfully
replicated in African Americans.
The 77 SNPs evaluable in whites separated into 55 LD
blocks. The thirteen SNPs in FGFR2 formed the largest
block, followed by ATM (5 SNPs) and TP53 (3 SNPs). LD
blocks consisting of 2 highly correlated SNPs were also
genotyped in caspase 8, apoptosis-related cysteine peptidase
gene (CASP8), cyclin-dependent kinase inhibitor 2A/B
genes(CDKN2A/CDKN2B),TOX3, andcytochromecoxidase
assembly homolog 11 gene (COX11). In African Americans,
the FGFR2 SNPs formed 3 separate blocks of 5, 4, and 2
SNPs, respectively, whereas the other 3 SNPs were not
strongly linked. One of the unlinked SNPs, rs1896395, was
not evaluable in whites (risk allele frequency = 0%). TOX3
contained two 2-SNP LD blocks, and TP53 contained a sin-
gle 3-SNP block. The 2 SNPs within CASP8, CDKN2A, and
COX11 were again in high LD. None of the ATM SNPs was
strongly correlated in African Americans. In total, the 73
SNPs evaluable in African Americans formed 58 LD blocks.
Semi-Bayes odds ratios and 95% posterior intervals for the
hierarchical models are presented in Tables 2 and 3 and Web
Figures 3 and 4. In general, the hierarchical-based estimates
had comparable or slightly lower precision than the MLE
odds ratios and consistently lower precision than the Bayes-
ian estimates. According to hierarchically derived estimates,
many of the SNPs in the larger LD blocks were not associated
with breast cancer. For example, MLE and Bayesian odds ra-
tios indicated that all 13 of the highly correlated FGFR2
SNPs were strongly associated with breast cancer among
whites, whereas the hierarchical model generated near-null
estimates for these SNPs. Of the 13, rs2981579 had the stron-
gest association (OR = 1.20, 95% posterior interval: 0.85,
1.72). Similarly, MLE and Bayesian models indicated that
10 of the 14 FGFR2 SNPs were associated with breast cancer
in African Americans, whereas hierarchical modeling pro-
duced elevated associations for 1 SNP in each LD block
(rs3750817, rs2981578, and rs2420946) and for 2 of 3 un-
linked SNPs.
DISCUSSION
Because several of the SNPs analyzed here were previ-
ously reported for this study population (54), we will limit
our discussion to novel findings. Among whites, statistically
significant associations for rs10757278 (in CDKN2A/
CDKN2B) and rs3104746 (in TOX3) have never before
been reported. We also corroborated previously observed as-
sociations between breast cancer and several well-validated
GWAS-identified SNPs, including 2 MRPS30 SNPs
(rs4415084 and rs10941679) (4, 35, 39, 55–61), rs1562430
in 8q24 (35, 36, 57), and rs4784227 in TOX3 (33, 62). Addi-
tionally, we replicated several less-established GWAS-
-identified SNPs, including rs704010 in ZMIZ1 (36) and
rs3750817, rs10736303, rs1078806, and rs2981578 in
FGFR2 (30, 31). The only CASP8, ATM, or TP53 SNP to
demonstrate a statistically significant association (rs9894986
in TP53) was not associated with disease in the study by
Zhang et al. (40).
We are the first to report a statistically significant associa-
tion for rs3750817 in FGFR2 in African Americans. Previous
investigations of rs2046210 (in ESR1) in African Americans
produced mostly near-null odds ratios (2–6, 11, 63), but sev-
eral of the FGFR2 and TOX3 SNPs were associated with
breast cancer in 1 or more prior investigations. This includes
rs10736303 and rs2981578 (in FGFR2) (5, 8) and rs3104746
and rs3112562 (in TOX3) (9). Both rs2981578 and rs3104746
were positively associated with disease in a pooled analysis
by Chen et al. (2), but approximately 20% of these partici-
pants were drawn from our study population. In general,
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Table 1. Frequencies of Breast Cancer Risk Alleles Among Whites and African Americans in the Carolina Breast Cancer Study, by Race and






















1p12 rs11249433 G 0.44 0.41 0.54 G 0.14 0.10 0.01
CASP8 rs1045485 G 0.88 0.87 0.63 C 0.06 0.05 0.74
CASP8 rs17468277 C 0.87 0.87 0.63 C 0.95 0.95 0.95
2q35 rs13387042 A 0.54 0.47 0.83 A 0.74 0.73 1.00
2p rs4666451 G 0.60 0.63 0.30 G 0.78 0.77 0.12
SLC4A rs4973768 T 0.48 0.42 0.22 T 0.36 0.40 0.05
4p rs12505080 C 0.29 0.24 0.80 C 0.17 0.17 0.64
TLR1 rs7696175 T 0.45 0.45 0.91 T 0.08 0.06 0.54
MRPS30 rs4415084 T 0.43 0.42 0.18 T 0.64 0.58 0.70
MRPS30 rs10941679 G 0.29 0.30 0.76 G 0.19 0.19 0.17
5p12 rs981782 T 0.53 0.59 0.26 T 0.92 0.91 0.60
5q rs30099 T 0.10 0.10 0.40 T 0.16 0.12 0.75
MAP3K rs889312 C 0.32 0.34 0.85 C 0.33 0.36 0.08
ESR1 rs2046210 A 0.36 0.35 0.48 A 0.64 0.61 0.15
ESR1 rs851974 G 0.42 0.43 0.28 G 0.17 0.17 0.46
ESR1 rs2077647 A 0.51 0.49 0.64 A 0.52 0.51 0.16
ESR1 rs2234693 T 0.53 0.57 0.45 T 0.47 0.48 0.63
ESR1 rs1801132 C 0.76 0.76 0.43 C 0.90 0.88 0.36
ESR1 rs3020314 C 0.36 0.34 0.15 C 0.69 0.71 0.75
ESR1 rs3798577 T 0.52 0.53 0.43 T 0.57 0.54 0.27
ECHDC1 rs2180341 G 0.25 0.27 0.55 G 0.31 0.33 0.83
RELN rs17157903 T 0.13 0.12 0.06 T 0.11 0.10 0.08
8q24 rs13281615 G 0.43 0.42 0.17 G 0.44 0.43 0.58
8q24 rs1562430 T 0.59 0.57 0.78 T 0.54 0.53 0.61
CDKN2A/B rs3731257 T 0.23 0.23 0.24 T 0.09 0.11 0.89
CDKN2A/B rs3731249 A 0.03 0.03 0.90 A 0.01 0.00 0.95
CDKN2A/B rs518394 G 0.44 0.48 0.17 G 0.08 0.08 0.06
CDKN2A/B rs564398 G 0.42 0.47 0.29 G 0.08 0.08 0.02
CDKN2A/B rs1011970 T 0.19 0.15 0.62 T 0.33 0.34 0.14
CDKN2A/B rs10757278 A 0.54 0.55 0.18 A 0.81 0.82 0.77
CDKN2A/B rs10811661 C 0.17 0.20 0.02 C 0.07 0.07 0.24
ANKRD16 rs2380205 C 0.56 0.60 0.88 C 0.42 0.46 0.72
ZNF365 rs10995190 G 0.86 0.82 0.76 G 0.83 0.83 0.90
ZMIZ1 rs704010 T 0.43 0.42 0.93 T 0.11 0.08 0.82
FGFR2 rs1896395 A 0.00 0.00 0.96 A 0.20 0.20 0.04
FGFR2 rs3750817 C 0.65 0.60 0.16 C 0.91 0.88 0.83
FGFR2 rs10736303 G 0.54 0.49 0.19 G 0.87 0.84 0.75
FGFR2 rs11200014 A 0.46 0.41 0.65 A 0.20 0.21 0.75
FGFR2 rs2981579 T 0.47 0.41 0.51 T 0.62 0.61 0.10
FGFR2 rs1078806 G 0.45 0.41 0.53 G 0.21 0.21 0.99
FGFR2 rs2981578 C 0.54 0.49 0.09 C 0.87 0.84 0.45
FGFR2 rs1219648 G 0.45 0.39 0.35 G 0.44 0.41 0.57
FGFR2 rs2912774 A 0.45 0.40 0.26 A 0.59 0.55 0.07
Table continues
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the SNPs identified in the candidate gene meta-analysis were
rarer and had weaker associations than the GWAS-identified
SNPs, making it difficult to detect meaningful associations.
As expected given our choice of null-centered priors, the
Bayesian estimates were closer to the null than the MLE es-























FGFR2 rs2936870 T 0.45 0.40 0.25 T 0.60 0.56 0.14
FGFR2 rs2420946 T 0.44 0.39 0.21 T 0.54 0.52 0.03
FGFR2 rs2162540 G 0.44 0.39 0.28 G 0.54 0.52 0.41
FGFR2 rs2981582 T 0.44 0.39 0.30 T 0.49 0.49 0.96
FGFR2 rs3135718 G 0.44 0.39 0.23 G 0.58 0.54 0.65
10q rs10510126 C 0.89 0.89 0.38 C 0.89 0.90 0.21
ATM rs1800054 G 0.02 0.02 0.34 G 0.00 0.00 0.94
ATM rs4986761 C 0.02 0.01 0.68 C 0.00 0.00 0.98
ATM rs1800056 C 0.02 0.01 0.67 C 0.00 0.00 0.95
ATM rs1800057 G 0.03 0.02 0.90 G 0.01 0.01 0.91
ATM rs1800058 T 0.02 0.02 0.06 T 0.01 0.01 0.91
ATM rs1801516 A 0.15 0.14 0.17 A 0.03 0.02 0.48
ATM rs3092992 C 0.06 0.04 0.13 C 0.01 0.01 0.77
ATM rs664143 C 0.58 0.57 0.70 C 0.66 0.66 0.45
ATM rs170548 G 0.31 0.37 0.88 G 0.09 0.12 0.07
ATM rs3092993 A 0.15 0.14 0.19 A 0.03 0.02 0.48
LSP1 rs3817198 C 0.33 0.34 0.18 C 0.17 0.17 0.16
LSP1 rs909116 T 0.54 0.52 0.20 T 0.71 0.72 0.96
MYEOV rs614367 T 0.18 0.11 0.05 T 0.13 0.15 0.33
H19 rs2107425 C 0.71 0.68 0.74 C 0.48 0.53 0.42
TOX3 rs8049149 T 0.00 0.00 0.98 T 0.02 0.02 0.32
TOX3 rs16951186 T 0.01 0.01 0.75 T 0.17 0.19 0.95
TOX3 rs8051542 T 0.46 0.44 0.43 T 0.35 0.30 0.12
TOX3 rs12443621 G 0.51 0.41 0.39 G 0.47 0.51 1.00
TOX3 rs3803662 T 0.32 0.24 0.73 C 0.48 0.46 0.65
TOX3 rs4784227 T 0.29 0.22 0.62 T 0.08 0.07 0.59
TOX3 rs3104746 A 0.03 0.02 0.48 A 0.26 0.18 0.87
TOX3 rs3112562 G 0.22 0.20 0.45 G 0.52 0.46 0.88
TOX3 rs9940048 A 0.26 0.24 0.50 A 0.31 0.30 0.64
TP53 rs9894946 G 0.82 0.84 0.48 G 0.95 0.95 0.25
TP53 rs1614984 T 0.41 0.39 0.22 T 0.40 0.40 0.03
TP53 rs4968187 T 0.00 0.00 0.93 T 0.01 0.00 0.92
TP53 rs12951053 C 0.07 0.06 0.47 C 0.11 0.11 0.09
TP53 rs17880604 C 0.02 0.01 0.21 C 0.00 0.00 0.95
TP53 rs1800372 G 0.02 0.02 0.54 G 0.00 0.00 0.98
TP53 rs2909430 G 0.15 0.13 0.66 G 0.27 0.24 0.64
TP53 rs1042522 C 0.75 0.77 0.64 C 0.39 0.43 0.77
TP53 rs8079544 C 0.95 0.95 1.00 C 0.89 0.89 0.83
COX11 rs7222197 G 0.71 0.75 0.60 G 0.66 0.65 0.70
COX11 rs6504950 G 0.71 0.75 0.59 G 0.67 0.65 0.66
Abbreviations: HWE, Hardy-Weinberg equilibrium; RAF, risk allele frequency; SNP, single nucleotide polymorphism.
a Weighted by inverse sampling probability.
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Table 2. Comparison of Odds Ratios and Confidence Limit Ratios or Posterior Limit Ratios for Maximum Likelihood Estimation, Bayesian, and
Hierarchical Regression Models Among White Women (1,247 Cases and 1,105 Controls) in the Carolina Breast Cancer Study, North Carolina,
1993–2001






ORa 95% CI ORb 95% CI CLR ORb 95% PI PLR ORc 95% PI PLR
1p12 rs11249433d 28 1.14 1.10, 1.19 1.09 0.96, 1.24 1.28 1.09 0.96, 1.22 1.28 1.09 0.96, 1.24 1.28
CASP8 block1 rs1045485e 33 1.12 1.08, 1.18 1.13 0.94, 1.35 1.43 1.11 0.93, 1.29 1.39 1.08 0.78, 1.49 1.90
CASP8 block1 rs17468277 1.12 0.93, 1.34 1.43 1.11 0.93, 1.29 1.38 1.04 0.76, 1.44 1.90
2q35 rs13387042d 27 1.20 1.14, 1.26 1.08 0.96, 1.22 1.28 1.08 0.96, 1.21 1.27 1.08 0.96, 1.22 1.28
2p rs4666451f 23 1.03 1.00, 1.06 1.02 0.90, 1.16 1.28 1.02 0.90, 1.14 1.27 1.02 0.90, 1.16 1.28
SLC4A7 rs4973768d 29 1.16 1.10, 1.24 1.04 0.92, 1.17 1.28 1.04 0.92, 1.17 1.28 1.04 0.92, 1.17 1.28
4p rs12505080f 25 1.15g 1.03, 1.28 1.06 0.92, 1.23 1.33 1.06 0.92, 1.21 1.31 1.06 0.92, 1.23 1.33
TLR1 rs7696175f 25 1.12g 1.00, 1.26 1.09 0.96, 1.23 1.28 1.09 0.96, 1.22 1.27 1.09 0.96, 1.23 1.28
MRPS30 rs4415084d 32 1.16 1.10, 1.21 1.23 1.08, 1.40 1.30 1.22 1.07, 1.37 1.28 1.23 1.08, 1.40 1.30
MRPS30 rs10941679f 32 1.19 1.13, 1.26 1.18 1.03, 1.36 1.32 1.17 1.01, 1.33 1.31 1.18 1.03, 1.36 1.32
5p12 rs981782d 23 1.04 1.01, 1.08 0.98 0.86, 1.11 1.28 0.98 0.87, 1.10 1.27 0.98 0.86, 1.11 1.28
5q rs30099f 23 1.05 1.01, 1.10 1.04 0.85, 1.28 1.52 1.04 0.84, 1.24 1.48 1.04 0.85, 1.28 1.52
MAP3K1 rs889312d 23 1.13 1.10, 1.16 1.19 1.04, 1.35 1.30 1.18 1.03, 1.32 1.29 1.19 1.04, 1.35 1.30
ESR1 rs2046210d 30 1.29 1.21, 1.37 1.09 0.96, 1.24 1.30 1.08 0.95, 1.22 1.28 1.09 0.96, 1.24 1.30
ESR1 rs851974 0.91 0.80, 1.03 1.29 0.91 0.81, 1.03 1.27 0.91 0.80, 1.03 1.29
ESR1 rs2077647 0.97 0.86, 1.10 1.28 0.97 0.86, 1.10 1.27 0.97 0.86, 1.10 1.28
ESR1 rs2234693 0.95 0.84, 1.07 1.28 0.95 0.84, 1.06 1.27 0.95 0.84, 1.07 1.28
ESR1 rs1801132e 33 1.05 1.00, 1.11 0.92 0.80, 1.06 1.34 0.93 0.80, 1.05 1.31 0.92 0.80, 1.06 1.34
ESR1 rs3020314e 33 1.12 1.06, 1.18 1.05 0.92, 1.19 1.29 1.05 0.93, 1.18 1.27 1.05 0.92, 1.19 1.29
ESR1 rs3798577 1.03 0.91, 1.17 1.28 1.03 0.91, 1.16 1.27 1.03 0.91, 1.17 1.28
ECHDC1 rs2180341d 24 1.41 1.25, 1.59 1.04 0.90, 1.20 1.34 1.04 0.89, 1.19 1.33 1.04 0.90, 1.20 1.34
RELN rs17157903f 25 1.11 1.00, 1.23 0.87 0.73, 1.04 1.42 0.89 0.75, 1.05 1.40 0.87 0.73, 1.04 1.42
8q24 rs13281615d 23 1.08 1.05, 1.11 1.11 0.98, 1.26 1.28 1.11 0.98, 1.24 1.26 1.11 0.98, 1.26 1.28
8q24 rs1562430d 29 1.17 1.10, 1.25 1.13 0.99, 1.28 1.29 1.12 0.99, 1.26 1.27 1.13 0.99, 1.28 1.29
CDKN2A/B rs3731257 0.93 0.81, 1.07 1.32 0.94 0.81, 1.07 1.31 0.93 0.81, 1.07 1.32
CDKN2A/B rs3731249 0.90 0.63, 1.28 2.04 0.94 0.68, 1.20 1.78 0.90 0.63, 1.29 2.04
CDKN2A/B block 1 rs518394 1.03 0.91, 1.16 1.28 1.03 0.91, 1.15 1.26 0.98 0.76, 1.27 1.28
CDKN2A/B block 1 rs564398 1.04 0.92, 1.17 1.28 1.04 0.91, 1.17 1.28 1.05 0.82, 1.36 1.67
CDKN2A/B rs1011970d 29 1.20 1.11, 1.30 1.13 0.96, 1.33 1.38 1.12 0.95, 1.30 1.36 1.13 0.96, 1.33 1.38
CDKN2A/B rs10757278 1.17 1.04, 1.33 1.28 1.16 1.01, 1.30 1.28 1.17 1.04, 1.33 1.28
CDKN2A/B rs10811661 1.00 0.85, 1.18 1.38 1.01 0.85, 1.16 1.36 1.00 0.85, 1.18 1.38
ANKRD16 rs2380205d 29 1.06 1.02, 1.10 1.01 0.89, 1.14 1.28 1.01 0.89, 1.14 1.27 1.01 0.89, 1.14 1.28
ZNF365 rs10995190d 29 1.16 1.10, 1.22 1.00 0.84, 1.20 1.43 1.00 0.85, 1.17 1.38 1.00 0.84, 1.20 1.43
ZMIZ1 rs704010d 29 1.07 1.03, 1.11 1.24 1.09, 1.41 1.29 1.23 1.08, 1.39 1.28 1.24 1.09, 1.41 1.29
FGFR2 block 1 rs3750817 1.24 1.09, 1.40 1.29 1.22 1.08, 1.37 1.28 0.97 0.81, 1.16 1.43
FGFR2 block 1 rs10736303f 23 1.25 1.18, 1.32 1.33 1.17, 1.50 1.28 1.31 1.15, 1.47 1.28 1.08 0.79, 1.48 1.88
FGFR2 block 1 rs11200014 1.30 1.15, 1.48 1.28 1.29 1.13, 1.44 1.27 0.94 0.66, 1.35 2.05
FGFR2 block 1 rs2981579d 28 1.17g 1.07, 1.27 1.33 1.18, 1.51 1.28 1.31 1.16, 1.48 1.27 1.20 0.85, 1.72 2.03
FGFR2 block 1 rs1078806f 24 1.26 1.13, 1.40 1.29 1.14, 1.46 1.28 1.28 1.14, 1.44 1.26 0.95 0.67, 1.34 1.99
FGFR2 block 1 rs2981578f 23 1.26 1.19, 1.34 1.32 1.17, 1.50 1.28 1.30 1.15, 1.45 1.26 1.11 0.81, 1.51 1.86
FGFR2 block 1 rs1219648d 25 1.27 1.18, 1.36 1.31 1.16, 1.48 1.28 1.29 1.14, 1.45 1.27 1.04 0.72, 1.51 2.10
FGFR2 block 1 rs2912774f 23 1.26 1.19, 1.34 1.30 1.15, 1.47 1.28 1.28 1.13, 1.44 1.27 0.96 0.65, 1.40 2.13
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Table 2. Continued






ORa 95% CI ORb 95% CI CLR ORb 95% PI PLR ORc 95% PI PLR
FGFR2 block 1 rs2936870f 23 1.26 1.19, 1.34 1.30 1.15, 1.47 1.28 1.29 1.13, 1.44 1.28 0.98 0.67, 1.44 2.14
FGFR2 block 1 rs2420946f 25 1.25 1.18, 1.36 1.30 1.15, 1.48 1.28 1.28 1.14, 1.45 1.27 0.99 0.67, 1.46 2.16
FGFR2 block 1 rs2162540 1.31 1.15, 1.48 1.28 1.29 1.13, 1.44 1.27 1.04 0.71, 1.52 2.10
FGFR2 block 1 rs2981582d 23 1.26 1.23, 1.30 1.30 1.15, 1.48 1.28 1.29 1.13, 1.44 1.28 1.01 0.69, 1.48 2.09
FGFR2 block 1 rs3135718f 23 1.15 1.07, 1.23 1.31 1.16, 1.48 1.28 1.29 1.14, 1.45 1.27 1.05 0.72, 1.51 2.04
10q rs10510126f 25 1.20 1.08, 1.35 1.11 0.91, 1.35 1.47 1.10 0.91, 1.31 1.43 1.11 0.91, 1.35 1.47
ATM rs1800054 1.01 0.65, 1.58 2.45 1.03 0.70, 1.42 2.03 1.01 0.65, 1.58 2.45
ATM rs1800057e 33 1.20h 1.01, 1.44 1.09 0.76, 1.56 2.06 1.08 0.78, 1.39 1.79 1.09 0.76, 1.56 2.06
ATM rs1800058 0.82 0.54, 1.25 2.33 0.90 0.62, 1.18 1.90 0.82 0.54, 1.25 2.34
ATM block 1 rs1801516 0.98 0.82, 1.17 1.43 0.99 0.84, 1.16 1.39 0.95 0.69, 1.32 1.94
ATM block 1 rs3092992 1.19 0.89, 1.60 1.80 1.16 0.87, 1.46 1.67 1.15 0.89, 1.49 1.68
ATM block 1 rs664143 1.02 0.90, 1.15 1.28 1.02 0.90, 1.14 1.27 1.10 0.92, 1.31 1.42
ATM block 1 rs170548 0.98 0.86, 1.12 1.31 0.98 0.86, 1.11 1.29 0.92 0.76, 1.11 1.50
ATM block 1 rs3092993 0.98 0.82, 1.18 1.43 0.99 0.83, 1.15 1.39 0.97 0.70, 1.35 1.94
LSP1 rs3817198d 23 1.07 1.04, 1.11 1.08 0.95, 1.24 1.30 1.08 0.95, 1.22 1.28 1.08 0.95, 1.24 1.30
LSP1 rs909116d 29 1.17 1.10, 1.24 1.14 1.01, 1.30 1.28 1.13 0.99, 1.27 1.28 1.14 1.01, 1.30 1.28
H19 rs2107425f 23 1.04 1.01, 1.08 1.54 1.30, 1.82 1.31 1.49 1.25, 1.74 1.29 1.54 1.30, 1.82 1.31
TOX3 rs16951186 1.15 1.00, 1.31 3.49 1.14 1.01, 1.30 2.26 1.15 1.00, 1.31 3.49
TOX3 rs8051542f 23 1.09 1.06, 1.13 1.12 0.99, 1.26 1.28 1.11 0.97, 1.23 1.27 1.12 0.99, 1.26 1.28
TOX3 rs1244362f 23 1.11 1.08, 1.14 1.17 1.04, 1.33 1.28 1.16 1.03, 1.31 1.27 1.17 1.04, 1.33 1.28
TOX3 block 1 rs3803662d 23 1.20 1.16, 1.24 1.27 1.11, 1.46 1.31 1.25 1.10, 1.42 1.29 1.14 0.91, 1.43 1.58
TOX3 block 1 rs4784227d 26 1.25 1.20, 1.31 1.26 1.09, 1.44 1.32 1.23 1.07, 1.41 1.31 1.11 0.88, 1.41 1.60
TOX3 rs3104746 1.66 1.10, 2.51 2.29 1.42 0.97, 1.94 2.01 1.66 1.10, 2.51 2.29
TOX3 rs3112562 0.99 0.86, 1.15 1.34 0.99 0.86, 1.13 1.32 0.99 0.86, 1.15 1.34
TOX3 rs9940048 1.03 0.89, 1.19 1.33 1.03 0.89, 1.17 1.32 1.03 0.89, 1.19 1.33
TP53 rs9894946 0.84 0.72, 0.99 1.38 0.86 0.73, 1.00 1.36 0.84 0.72, 0.99 1.38
TP53 rs1614984 1.03 0.91, 1.17 1.28 1.03 0.92, 1.15 1.26 1.03 0.91, 1.17 1.28
TP53 rs12951053e 33 1.15 1.04, 1.26 1.09 0.85, 1.39 1.63 1.08 0.83, 1.32 1.58 1.09 0.85, 1.39 1.63
TP53 rs17880604 0.82 0.51, 1.33 2.62 0.92 0.61, 1.26 2.06 0.82 0.51, 1.33 2.62
TP53 block 1 rs1800372 0.88 0.55, 1.40 2.57 0.95 0.64, 1.30 2.03 0.95 0.68, 1.32 1.94
TP53 block 1 rs2909430 1.11 0.93, 1.33 1.43 1.10 0.92, 1.29 1.41 1.16 0.91, 1.49 1.51
TP53 block 1 rs1042522 0.98 0.85, 1.13 1.33 0.99 0.85, 1.12 1.31 1.06 0.89, 1.26 1.40
TP53 rs8079544 1.24 0.95, 1.63 1.72 1.19 0.92, 1.50 1.63 1.24 0.95, 1.63 1.72
COX11 block 1 rs7222197f 29 1.12 1.04, 1.20 0.98 0.85, 1.12 1.32 0.98 0.86, 1.12 1.29 0.99 0.72, 1.36 1.89
COX11 block 1 rs6504950f 31 1.05 1.03, 1.09 0.98 0.85, 1.12 1.32 0.98 0.84, 1.11 1.31 0.99 0.72, 1.36 1.89
Abbreviations: CI, confidence interval; CLR, confidence limit ratio; GWAS, genome-wide association study; LD, linkage disequilibrium; MLE,
maximum likelihood estimated; OR, odds ratio; PI, posterior interval; PLR, posterior limit ratio; SNP, single nucleotide polymorphism.
a Odds ratios from initial GWAS or candidate gene meta-analyses (if met criteria for cumulative evidence of association); all odds ratios for
log-additive genetic models, unless otherwise specified. Those without values are not GWAS hits and were not included in the candidate gene
meta-analysis.
b Adjusted for age at diagnosis (cases) or selection (controls) and proportion of African ancestry.
c Adjusted for age at diagnosis (case) or selection (controls), proportion of African ancestry, and other SNPs in LD block.
d Previous GWAS hit.
e Cumulative evidence of an association in the meta-analysis by Zhang et al. (40).
f Other GWAS-identified gene.
g Odds ratio estimated using general genetic model.
h Odds ratio estimated using dominant genetic model.
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Table 3. Comparison of Odds Ratios and Confidence Limit Ratios or Posterior Limit Ratios for Frequentist, Basic Hierarchical, and Bayesian
Regression Models Among African American Women (766 Cases and 681 Controls) in the Carolina Breast Cancer Study, North Carolina,
1993–2001






ORa 95% CI ORb 95% CI CLR ORb 95% PI PLR ORc 95% PI PLR
1p12 rs11249433d 28 1.14 1.10, 1.19 1.26 0.99, 1.60 1.61 1.22 0.96, 1.48 1.53 1.26 0.99, 1.60 1.61
CASP8 block 1 rs1045485e 33 1.12 1.08, 1.18 0.93 0.67, 1.29 1.93 0.96 0.69, 1.22 1.77 1.12 0.39, 3.17 8.05
CASP8 block 1 rs17468277 1.09 0.78, 1.54 1.99 1.07 0.78, 1.38 1.78 1.20 0.41, 3.53 8.68
2q35 rs13387042d 27 1.20 1.14, 1.26 1.02 0.86, 1.22 1.43 1.02 0.86, 1.20 1.39 1.02 0.86, 1.22 1.43
2p rs4666451f 23 1.03 1.00, 1.06 1.15 0.96, 1.39 1.45 1.13 0.95, 1.34 1.41 1.15 0.96, 1.39 1.45
SLC4A7 rs4973768d 29 1.16 1.10, 1.24 0.90 0.77, 1.06 1.38 0.91 0.77, 1.04 1.35 0.90 0.77, 1.06 1.38
4p rs12505080f 25 1.15g 1.03, 1.28 1.09 0.88, 1.34 1.52 1.08 0.88, 1.30 1.48 1.09 0.88, 1.34 1.52
TLR1 rs7696175f 25 1.12g 1.00, 1.26 1.39 1.04, 1.86 1.79 1.29 0.99, 1.66 1.68 1.39 1.04, 1.86 1.80
MRPS30 rs4415084d 32 1.16 1.10, 1.21 1.13 0.97, 1.33 1.38 1.13 0.96, 1.30 1.35 1.13 0.97, 1.33 1.38
MRPS30 rs10941679f 32 1.19 1.13, 1.26 1.00 0.82, 1.22 1.49 1.01 0.83, 1.19 1.43 1.00 0.82, 1.22 1.49
5p12 rs981782d 23 1.04 1.01, 1.08 1.11 0.84, 1.46 1.74 1.09 0.84, 1.36 1.61 1.11 0.84, 1.46 1.74
5q rs30099f 23 1.05 1.01, 1.10 1.22 0.98, 1.52 1.55 1.19 0.96, 1.44 1.50 1.22 0.98, 1.52 1.55
MAP3K1 rs889312d 23 1.13 1.10, 1.16 0.95 0.80, 1.13 1.41 0.96 0.81, 1.11 1.37 0.95 0.80, 1.13 1.41
ESR1 rs2046210d 30 1.29 1.21, 1.37 1.22 1.04, 1.43 1.38 1.20 1.03, 1.39 1.35 1.22 1.04, 1.43 1.38
ESR1 rs851974 0.93 0.76, 1.14 1.50 0.94 0.78, 1.13 1.45 0.93 0.75, 1.14 1.50
ESR1 rs2077647 1.07 0.92, 1.25 1.37 1.07 0.92, 1.23 1.34 1.07 0.92, 1.25 1.37
ESR1 rs2234693 0.96 0.82, 1.13 1.37 0.97 0.83, 1.12 1.35 0.96 0.82, 1.13 1.37
ESR1 rs1801132e 33 1.05 1.00, 1.11 1.19 0.93, 1.52 1.64 1.16 0.91, 1.42 1.55 1.19 0.93, 1.52 1.64
ESR1 rs3020314e 33 1.12 1.06,1.18 1.00 0.84, 1.19 1.41 1.01 0.85, 1.17 1.37 1.00 0.84, 1.19 1.41
ESR1 rs3798577 1.02 0.88, 1.19 1.36 1.02 0.89, 1.18 1.33 1.02 0.87, 1.19 1.36
ECHDC1 rs2180341d 24 1.41 1.25, 1.59 0.98 0.83, 1.15 1.39 0.98 0.84, 1.14 1.36 0.98 0.83, 1.15 1.39
RELN rs17157903f 25 1.11 1.00, 1.23 1.07 0.83, 1.37 1.64 1.07 0.85, 1.31 1.54 1.07 0.83, 1.37 1.64
8q24 rs13281615d 23 1.08 1.05, 1.11 1.00 0.86, 1.18 1.38 1.01 0.85, 1.17 1.37 1.00 0.86, 1.18 1.38
8q24 rs1562430d 29 1.17 1.10, 1.25 1.00 0.86, 1.17 1.36 1.00 0.87, 1.16 1.34 1.00 0.86, 1.17 1.36
CDKN2A/B rs3731257 0.88 0.67, 1.15 1.71 0.91 0.71, 1.14 1.60 0.88 0.67, 1.15 1.71
CDKN2A/B block 1 rs518394 1.01 0.76, 1.35 1.76 1.02 0.78, 1.28 1.64 1.01 0.73, 1.40 1.76
CDKN2A/B block 1 rs564398 1.01 0.75, 1.35 1.79 1.01 0.77, 1.27 1.66 1.00 0.72, 1.40 1.96
CDKN2A/B rs1011970d 29 1.20 1.11, 1.30 0.95 0.81, 1.11 1.38 0.96 0.82, 1.10 1.34 0.95 0.81, 1.11 1.38
CDKN2A/B rs10757278 0.91 0.75, 1.12 1.50 0.93 0.76, 1.09 1.44 0.91 0.75, 1.12 1.50
CDKN2A/B rs10811661 1.00 0.74, 1.35 1.83 1.01 0.76, 1.28 1.67 1.00 0.74, 1.35 1.83
ANKRD16 rs2380205d 29 1.06 1.02, 1.10 0.97 0.83, 1.13 1.37 0.98 0.84, 1.13 1.34 0.97 0.83, 1.13 1.37
ZNF365 rs10995190d 29 1.16 1.10, 1.22 1.06 0.87, 1.29 1.49 1.05 0.86, 1.23 1.44 1.06 0.87, 1.29 1.49
ZMIZ1 rs704010d 29 1.07 1.03, 1.11 1.05 0.80, 1.36 1.69 1.04 0.80, 1.28 1.61 1.05 0.80, 1.36 1.69
FGFR2 rs1896395 1.01 0.83, 1.23 1.48 1.02 0.84, 1.20 1.44 1.01 0.83, 1.23 1.48
FGFR2 block 1 rs3750817 1.74 1.34, 2.26 1.69 1.61 1.22, 2.02 1.66 1.38 1.05, 1.83 1.74
FGFR2 block 1 rs10736303f 23 1.25 1.18, 1.32 1.39 1.12, 1.74 1.56 1.33 1.07, 1.61 1.51 1.08 0.83, 1.39 1.67
FGFR2 block 1 rs11200014 1.04 0.86, 1.26 1.47 1.04 0.85, 1.23 1.45 0.97 0.70, 1.34 1.92
FGFR2 block 1 rs2981579d 28 1.17g 1.07, 1.27 1.22 1.04, 1.42 1.36 1.19 1.03, 1.37 1.33 1.10 0.93, 1.31 1.41
FGFR2 block 1 rs1078806f 24 1.26 1.13, 1.40 1.06 0.88, 1.29 1.47 1.06 0.87, 1.25 1.43 1.00 0.72, 1.38 1.92
FGFR2 block 2 rs2981578f 23 1.26 1.19, 1.34 1.42 1.14, 1.77 1.56 1.36 1.10, 1.65 1.51 1.23 0.99, 1.53 1.54
FGFR2 block 2 rs1219648d 25 1.27 1.18, 1.36 1.19 1.02, 1.39 1.37 1.18 1.01, 1.35 1.33 1.01 0.82, 1.24 1.51
FGFR2 block 2 rs2912774f 23 1.26 1.19, 1.34 1.27 1.09, 1.49 1.37 1.25 1.06, 1.43 1.35 1.09 0.80, 1.49 1.85
FGFR2 block 2 rs2936870f 23 1.26 1.19, 1.34 1.27 1.09, 1.48 1.37 1.25 1.07, 1.44 1.34 1.09 0.80, 1.48 1.84
FGFR2 block 3 rs2420946f 25 1.25 1.18, 1.36 1.17 1.00, 1.37 1.37 1.16 1.00, 1.35 1.35 0.95 0.72, 1.25 1.73
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for many of the SNPs assessed here, the degree of attenuation
was strongest when the SNP’s minor allele frequency was
low. These results demonstrate how Bayesian methods are
less vulnerable to extreme observations, and why Bayesian
methods are particularly advantageous when data are sparse
or there is a high probability of spurious associations. In this
way, Bayesian methods may be a less conservative alternative
to standard multiple comparisons adjustment methods.
Because the hierarchical models included more parameters
than the MLE or Bayesian models, they did not improve pre-
cision. However, these methods can help to differentiate in-
dividual effects of highly correlated SNPs. For example, it is
unlikely that all 13 evaluable FGFR2 SNPs are strongly asso-
ciated with breast cancer in whites. Rather, 1 or 2 causal var-
iants within the LD block probably drive all of the observed
associations. In such scenarios, hierarchical models can
Table 3. Continued






ORa 95% CI ORb 95% CI CLR ORb 95% PI PLR ORc 95% PI PLR
FGFR2 block 3 rs2162540 1.23 1.05, 1.44 1.36 1.21 1.04, 1.40 1.34 1.27 0.96, 1.66 1.37
FGFR2 rs2981582d 23 1.26 1.23, 1.30 1.19 1.02, 1.39 1.37 1.18 1.00, 1.35 1.35 1.19 1.02, 1.39 1.37
FGFR2 rs3135718f 23 1.15 1.07, 1.23 1.26 1.08, 1.46 1.35 1.24 1.07, 1.43 1.33 1.26 1.08, 1.46 1.35
10q rs10510126f 25 1.20 1.08, 1.35 1.04 0.82, 1.32 1.61 1.04 0.82, 1.25 1.53 1.04 0.82, 1.32 1.61
ATM rs1801516 1.22 0.77, 1.95 2.54 1.14 0.76, 1.58 2.08 1.22 0.77, 1.95 2.54
ATM rs664143 0.95 0.81, 1.11 1.38 0.96 0.82, 1.10 1.35 0.95 0.81, 1.11 1.38
ATM rs170548 0.86 0.67, 1.11 1.66 0.90 0.70, 1.10 1.57 0.86 0.67, 1.11 1.66
ATM rs3092993 1.22 0.77, 1.95 2.54 1.14 0.76, 1.58 2.08 1.22 0.77, 1.95 2.54
LSP1 rs3817198d 23 1.07 1.04, 1.11 1.01 0.82, 1.24 1.52 1.01 0.84, 1.21 1.47 1.01 0.82, 1.24 1.52
LSP1 rs909116d 29 1.17 1.10, 1.24 1.00 0.84, 1.19 1.42 1.01 0.84, 1.17 1.39 1.00 0.84, 1.19 1.42
H19 rs2107425f 23 1.04 1.01, 1.08 0.84 0.71, 0.98 1.38 0.86 0.73, 0.98 1.35 0.84 0.71, 0.98 1.38
TOX3 rs8049149 0.92 0.54, 1.56 2.87 0.98 0.64, 1.35 2.10 0.92 0.54, 1.56 2.87
TOX3 rs16951186 0.90 0.74, 1.09 1.49 0.92 0.76, 1.10 1.45 0.90 0.74, 1.09 1.49
TOX3 rs8051542f 23 1.09 1.06, 1.13 1.14 0.97, 1.35 1.39 1.13 0.97, 1.30 1.35 1.14 0.97, 1.35 1.39
TOX3 rs12443621f 23 1.11 1.08, 1.14 0.86 0.74, 1.01 1.36 0.88 0.75, 1.00 1.34 0.86 0.74, 1.01 1.36
TOX3 block 1 rs3803662d 23 1.20 1.16, 1.24 1.06 0.90, 1.23 1.37 1.05 0.91, 1.21 1.34 1.11 0.94, 1.31 1.39
TOX3 block 1 rs4784227d 26 1.25 1.20, 1.31 1.25 0.93, 1.67 1.80 1.19 0.90, 1.51 1.67 1.28 0.96, 1.71 1.77
TOX3 block 2 rs3104746 1.54 1.27, 1.86 1.46 1.49 1.22, 1.75 1.43 1.39 1.14, 1.71 1.50
TOX3 block 2 rs3112562 1.28 1.09, 1.50 1.37 1.26 1.09, 1.46 1.35 1.12 0.94, 1.33 1.41
TOX3 rs9940048 1.10 0.93, 1.31 1.40 1.10 0.92, 1.29 1.39 1.10 0.93, 1.31 1.41
TP53 rs9894946 0.96 0.68, 1.36 2.01 0.98 0.70, 1.28 1.82 0.96 0.68, 1.37 2.01
TP53 rs1614984 1.07 0.92, 1.25 1.36 1.07 0.91, 1.22 1.34 1.07 0.92, 1.25 1.36
TP53 block 1 rs12951053e 33 1.15 1.04, 1.26 1.03 0.80, 1.32 1.64 1.03 0.81, 1.25 1.55 1.01 0.77, 1.32 1.71
TP53 block 1 rs2909430 1.06 0.89, 1.25 1.40 1.06 0.89, 1.22 1.37 1.04 0.84, 1.28 1.52
TP53 block 1 rs1042522 0.98 0.83, 1.15 1.38 0.98 0.83, 1.13 1.36 1.00 0.82, 1.22 1.50
TP53 rs8079544 0.89 0.69, 1.15 1.66 0.92 0.72, 1.12 1.57 0.89 0.69, 1.15 1.66
COX11 block 1 rs7222197f 29 1.12 1.04, 1.20 1.14 0.97, 1.33 1.38 1.12 0.95, 1.29 1.36 1.07 0.77, 1.47 1.90
COX11 block 1 rs6504950f 31 1.05 1.03, 1.09 1.13 0.96, 1.32 1.37 1.12 0.95, 1.28 1.35 1.07 0.77, 1.47 1.90
Abbreviations: CI, confidence interval; CLR, confidence limit ratio; GWAS, genome-wide association study; LD, linkage disequilibrium; MLE,
maximum likelihood estimated; OR, odds ratio; PI, posterior interval; PLR, posterior limit ratio; SNP, single nucleotide polymorphism.
a Odds ratios from initial GWAS or candidate gene meta-analyses (if met criteria for cumulative evidence of association); all odds ratios for
log-additive genetic models, unless otherwise specified. Those without values are not GWAS hits and were not included in the candidate gene
meta-analysis.
b Adjusted for age at diagnosis (cases) or selection (controls) and proportion of African ancestry.
c Adjusted for age at diagnosis (cases) or selection (controls), proportion of African ancestry, and other SNPs in the LD block.
d Previous GWAS hit.
e Cumulative evidence of an association in the meta-analysis by Zhang et al. (40).
f Other GWAS-identified gene.
g Odds ratio estimated using general genetic model.
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effectively accommodate correlated exposures and provide
stable SNP- and haplotype-level odds ratios, whereas models
that evaluate all the SNPs simultaneously in a single-level
model will often produce unstable or nonconvergent esti-
mates (22, 48, 64).
Unfortunately, although we believe these methods would
be beneficial in larger studies, we did not have sufficient
power to reliably differentiate between the strongest FGFR2
SNP odds ratios and the null when so many SNPs were as-
sessed simultaneously. Analyses of SNPs in the other multi-
-SNP LD blocks were relatively more precise, but also largely
inconclusive. The hierarchical models performed better in
African Americans, with rs3750817, rs2981578, rs2420946,
and rs3104746 demonstrating notably stronger associations
than the other SNP(s) in their respective LD blocks. This per-
formance improvement is likely attributable to the anticipated
racial differences in LD block size.
We believe our specifications of prior means and variances
are reasonable. First, aside from mutations in BRCA1/
BRCA2, it is unlikely that a single SNP has a large effect
on breast cancer risk (20). Second, as long as the covariate
priors are appropriately specified, Bayesian analysis with
null-centered priors will bias effect estimates toward the
null (65). Lastly, we believe that correlated SNPs within an
LD block meet the criteria for exchangeability.
After we accounted for our sampling mechanisms, the only
observed discrepancy between study cases and other North
Carolina cases was that African Americans with later stage
disease were underrepresented in our study (66). Therefore,
odds ratios could be biased if the evaluated SNP is related
to disease aggressiveness or medical care utilization. With re-
gard to genotyping, whites were more likely to provide blood
samples than African Americans, but blood donation status
did not differ by case status, disease stage, or other known
risk factors.
The inclusion of in situ cases could bias estimates of SNPs
associated with disease aggressiveness or progression, but
given strong evidence that invasive and in situ tumors have
similar risk profiles (16, 67), we chose to retain these individ-
uals. Analyses limited to invasive cases yielded similar re-
sults (Web Table 2).
This was a racially diverse, population-based sample with
well-validated data. The inclusion of a relatively large sample
of African-American women allowed us to investigate racial
differences in genetic risk factors and, accordingly, provide
information that may help pinpoint causal variants. Although
the results for SNPs that violated Hardy-Weinberg equilib-
rium should be interpreted with caution, the quality control
measures used during the genotyping process should have re-
duced the number and impact of genotype misclassification.
In this analysis, we replicated several previously identified
breast cancer susceptibility loci in whites and African Amer-
icans by using bothMLEandBayesianmethods. Ourfindings
offer additional evidence that these SNPs or chromosomal re-
gions play an important role in breast cancer etiology. The
SNPs that replicated in African Americans are especially in-
structive, because they refine the genomic region containing
the causal variant. Our use of Bayesian methods to incorpo-
rate external information further augments the utility of these
results. We believe that fine-mapping studies and smaller,
etiologically driven investigations may derive even greater
benefit from these better-informed, more stable approaches.
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